Astal Laboratories board to consider Q4FY26 and FY26 results on May 30

1 min read     Updated on 25 May 2026, 08:15 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Astal Laboratories Limited will hold a board meeting on May 30, 2026, to consider the audited standalone and consolidated financial results for Q4FY26 and FY26. The board will also review the audited financial statements for the year ended March 31, 2026 and appoint an internal auditor for FY27. The trading window for designated persons remains closed until 48 hours after the meeting.

powered bylight_fuzz_icon
41265902

*this image is generated using AI for illustrative purposes only.

Astal Laboratories Limited has scheduled a board meeting on May 30, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The meeting will be held at the company's corporate office in Telangana to review the financial performance for Q4FY26 and the full fiscal year FY26.

The board will deliberate on the audited standalone and consolidated financial statements for the financial year ended March 31, 2026, along with the report of the auditors. Additionally, the directors will consider the appointment of an internal auditor for the financial year 2026-27.

The trading window for designated persons and their immediate relatives has been closed since April 01, 2026, in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015. This window will remain closed until forty-eight hours after the conclusion of the board meeting.

The meeting agenda includes the consideration of the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, accompanied by the limited review report of the auditors. Any other matter with the permission of the chair may also be taken up during the meeting.

Key Meeting Details

Agenda Item Description
Financial Results Audited standalone and consolidated results for Q4FY26 and FY26
Financial Statements Audited standalone and consolidated statements for FY26
Internal Auditor Appointment for FY27
Trading Window Closed from April 01, 2026 until 48 hours post-meeting

Historical Stock Returns for Astal Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+2.72%-4.61%+16.61%-13.08%-10.17%+741.60%

How will the FY26 financial performance influence Astal Laboratories' capital allocation strategy for the upcoming fiscal year?

What strategic shifts or growth initiatives is the company likely to prioritize based on the full-year audited results?

Could the appointment of a new internal auditor signal a shift in the company's risk management or compliance framework?

Astal Laboratories subsidiary appoints new statutory auditor

1 min read     Updated on 20 May 2026, 02:43 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Astal Laboratories Limited's subsidiary, Sriven Pharmachem India Private Limited, appointed M/s. Khedar Ankur & Associates Chartered Accountants as its statutory auditor effective May 19, 2026. This fills the vacancy left by the resignation of M/s. Balaji V & Co.

powered bylight_fuzz_icon
40813946

*this image is generated using AI for illustrative purposes only.

Astal Laboratories Limited has disclosed the appointment of a new statutory auditor for its material wholly owned subsidiary, M/s. Sriven Pharmachem India Private Limited. This decision was taken during the board meeting of the subsidiary held on May 19, 2026, to fill the casual vacancy caused by the resignation of M/s. Balaji V & Co.

The board approved the appointment of M/s. Khedar Ankur & Associates Chartered Accountants, bearing Firm Registration Number 040042N. The appointment is effective from May 19, 2026. The firm is a professionally managed proprietorship based in Delhi, led by CA Ankur Khedar.

Auditor Profile

M/s. Khedar Ankur & Associates provides a wide range of professional services. These include statutory audits, internal audits, tax audits, and direct and indirect taxation. The firm also offers GST advisory and compliance, accounting and financial reporting support, certification services, and other regulatory advisory assignments across diverse sectors.

Appointment Details

The following table summarizes the key details regarding the change in statutory auditors:

Particulars Details
Name of the Firm M/s. Khedar Ankur & Associates Chartered Accountants
Firm Registration Number 040042N
Reason for change Appointment of Auditor
Date of appointment May 19, 2026

The disclosure was made to the stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Historical Stock Returns for Astal Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+2.72%-4.61%+16.61%-13.08%-10.17%+741.60%

What were the specific reasons behind M/s. Balaji V & Co.'s resignation, and could those circumstances signal any underlying financial or governance concerns at Sriven Pharmachem India Private Limited?

How might the transition to a smaller Delhi-based proprietorship firm impact the audit quality and regulatory scrutiny of Astal Laboratories' material subsidiary going forward?

Will the auditor change at the subsidiary level prompt Astal Laboratories to review or realign its audit arrangements at the parent company level as well?

More News on Astal Laboratories

1 Year Returns:-10.17%